Byetta, Januvia Pancreatic Cancer Side Effects Being Reviewed in Europe

The diabetes drugs Byetta, Januvia, and Victoza are now under investigation by European health officials due to possible ties to pancreatic cancer and pancreatitis. 

On March 26, the European Medicines Agency (EMA) announced that it is looking into potential side effects uncovered by a recent study that also led the FDA to launch a similar investigation earlier this month into the pancreatic cancer risk with the diabetes drugs.

Byetta, Januvia and Victoza, as well as several other drugs, belong to a family of diabetes medications known as incretin mimetics, which mimic the incretin hormones the body uses to stimulate the production of insulin. They are used to lower blood sugar in people with type 2 diabetes.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Both investigations come after a study published last week in the medical journal Diabetes found evidence of increased pancreatic mass and precancerous cells among organ donors with type 2 diabetes treated with incretin mimetics. The findings raise serious concerns about the risk of pancreatitis and the development of cells with the potential to evolve into tumors.

Neither the FDA nor the EMA has made any recommendations in regards to changing the use of the drugs. Both recommend that patients continue to take the drugs as prescribed and that doctors continue to prescribe them in accordance with the product information.

Pancreatitis concerns have circulated around the drugs since 2007, when Byetta was linked to 30 reports of acute pancreatitis. In August 2008, the FDA notified doctors about six more cases of severe pancreatitis with Byetta, including two deaths. Following the FDA announcement, the drug makers disclosed that they were aware of at least four other pancreatitis deaths among Byetta users.

Concerns about the side effects of Byetta and Januvia were heightened last month, when a study published in JAMA Internal Medicine suggested that taking Byetta or Januvia may double the risk of hospitalization due to pancreatitis and researchers expressed concern that this may ultimately caused some users to develop pancreatic cancer, since chronic pancreatitis is a known risk factor for the development of pancreatic cancer.

A number of former users of the diabetes drugs who have been diagnosed with pancreatic cancer are already pursuing Byetta lawsuits, Januvia lawsuits and Victoza lawsuits, alleging that the drug manufacturers have ignored information about the potential toxicity to the pancreas and failed to warn about the potential pancreatic cancer side effects.

Image Credit: |


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

AT&T Data Breach Class Action Claims Telecom Giant
AT&T Data Breach Class Action Claims Telecom Giant "Disregarded" Customer Financial Safety (Posted today)

A Missouri woman is one of the latest person to file an class action claim over the AT&T data breach, after the telecom company admitted that hackers stole millions of customers' personal information and sold it on the internet.

Plaintiffs Oppose Phased Discovery Over Suboxone Tooth Decay Risks in MDL
Plaintiffs Oppose Phased Discovery Over Suboxone Tooth Decay Risks in MDL (Posted yesterday)

Plaintiffs say a federal judge should not waste time on a phased discovery plan requiring them to first prove Suboxone strips can cause tooth decay, saying the science is obvious and such a plan could delay resolution of hundreds of product liability lawsuits.